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genetic information is translated from a nucleic acid code 
into an amino acidic language to make proteins. Global pro-
tein synthesis rates have a key role in governing cell growth, 
the control of cell size, and cell proliferation. Changes in the 
levels of specific regulatory proteins involved in the transla-
tion process may affect the translation rates and the amount 
of produced proteins. Thus, the regulation of gene expres-
sion is a crucial step in cellular physiology considering that 
subtle defects in the mechanism of translational control may 
lead to either cell malignancy or cell death. Protein synthe-
sis is mainly regulated at the initiation step. In eukaryotes, 
initiation can be divided into two steps: formation of a 48S 
initiation complex and its joining with a 60S subunit [1]. 
First, the eukaryotic initiation factors eIF3, eIF1, eIF1A and 
eIF2-GTP-Met-tRNAi bind to the 40S ribosomal subunit 
to form a 43S preinitiation complex. This complex subse-
quently attaches to the 5′-proximal region of mRNAs, after 
which eIF4A, 4B and 4F unwind their secondary structure. 
The 43S complex then scans the 5′ untranslated region in 
the 5′–3′ direction until the initiation codon, where it stops 
and forms a 48S complex with codon–anticodon base-pair-
ing through eIF5. Second, eIF5B promotes the displacement 
of the eukaryotic initiation factors and the subsequent join-
ing of 48S complex with the 60S subunit [1].
The largest and more complex eukaryotic initiation fac-
tor, which plays a role in translation regulation, cell growth 
and cancer, is eIF3. This review is focused on the function 
of the f-subunit of eIF3 (eIF3f) in the translation regulation 
process. An analysis of its physiological significance and its 
intracellular interacting partners involved in translational 
regulation both in cancer and muscle cells is sequentially 
detailed. The aim is to delineate the global eIF3f interac-
tion network and to clarify its intracellular role in order to 
validate eIF3f as a lead candidate to use for biotherapeutic 
applications.
Abstract The regulation of the protein synthesis has a 
crucial role in governing the eukaryotic cell growth. Subtle 
changes of proteins involved in the translation process may 
alter the rate of the protein synthesis and modify the cell fate 
by shifting the balance from normal status into a tumoral 
or apoptotic one. The largest eukaryotic initiation factor 
involved in translation regulation is eIF3. Amongst the 13 
factors constituting eIF3, the f subunit finely regulates this 
balance in a cell-type-specific manner. Loss of this factor 
causes malignancy in several cells, and atrophy in normal 
muscle cells. The intracellular interacting partners which 
influence its physiological significance in both cancer and 
muscle cells are detailed in this review. By delineating the 
global interaction network of this factor and by clarifying 
its intracellular role, it becomes apparent that the f subunit 
represents a promising candidate molecule to use for bio-
therapeutic applications.
Keywords Apoptosis · Atrophy · Cancer · eIF3f · 
Hypertrophy
Introduction
Protein synthesis is one of the most complex and energy-
consuming processes in eukaryotic cells, by which the 
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Eukaryotic initiation factor 3
Translation initiation in eukaryotes is an intricate process 
requiring at least nine eukaryotic initiation factors [1, 2]. 
Among these factors, eIF3 is the largest as it comprises up 
to 13 non-identical subunits. Several functions have been 
ascribed to eIF3, including the interaction and stabilization 
of the eIF2-GTP-Met-tRNAi ternary complex, binding to 
the 40S ribosomal subunit, facilitating the binding of mRNA 
to the 40S ribosome, and promoting dissociation of the 40S 
and 60S ribosomal subunits. Other initiation factors (e.g., 
eIF4G, eIF4B, eIF5 and eIF1) are known to interact with 
eIF3, suggesting that this factor might have a role in ‘organ-
izing’ proteins on the surface of the 40S ribosome [3–5].
Structure and nomenclature
Mammalian eIF3 is an 800-kDa molecular mass assembly 
of 13 subunits that are designated eIF3a–eIF3m [3–11]. In 
the past, ad hoc nomenclatures for eIF3 subunits have been 
derived from subunit molecular weights or gene names. 
In 2001, to eliminate confusion surrounding cross-species 
comparisons of eIF3 subunits, a unified nomenclature was 
proposed by Browning et al. [7]. Each subunit is identified 
by a letter designation based on the decreasing order of the 
mammalian subunit masses determined from SDS-PAGE 
mobility (Table 1). For two novel subunits, −l and −m, the 
nomenclature has been adapted as they have arisen.
Initial characterizations of mammalian eIF3 were based on 
biochemical methods applied to purified proteins from rabbit 
reticulocytes and HeLa cells [12, 13]. Due to its large size 
and complexity, a detailed understanding of eIF3 structure 
and function has been achieved more recently from experi-
ments based on the cloning and characterization of human 
cDNAs encoding the eIF3 subunits [5, 14–16]. By compar-
ing the cDNA sequences of the mammalian eIF3 subunits 
to the entire genome of the budding yeast Saccharomyces 
cerevisiae, it appears that only five mammalian subunits 
eIF3-a, -b, -c, -g and -i have identifiable homologues encoded 
in yeast (Table 1). A sixth ortholog, eIF3j, is a nonessential 
subunit of the budding yeast eIF3 that enhances interactions 
with other eIFs [17], promotes binding of eIF3 to the 40S 
subunit [18], and has an independent function in 40S ribo-
some biogenesis [19]. Biochemical interactions have been 
detected between these five conserved subunits in both mam-
malian and yeast systems [14, 15, 20]. The S. cerevisiae eIF3 
complex also contains 3 additional proteins, p135, p62 and 
p16, for which corresponding homologs are not found in the 
mammalian complex [21–23], whereas 7 subunits (eIF3-d, 
-e, -f, -h, -k, -l and -m) identified in the mammalian eIF3 
complex are absent in the yeast complex (Table 1). Most 
of these 7 mammalian subunits of eIF3 appear to be highly 
conserved in Drosophila melanogaster, Caernorhabditis 
elegans, Arabidopsis thaliana and the fission yeast Schizo-
saccharomyces pombe [4, 5]. Nevertheless, the biochemical 
function of this complex is conserved inasmuch as eIF3 puri-
fied from S. cerevisiae can replace mammalian eIF3 in the 
Table 1  Summary of eukaryotic eIF3 subunits
Unified nomenclature S. cerevisiae + MW H. sapiens S. pombe A. thaliana Consensus motif
eIF3a Tif32—110 kDa p170 p107 p114 PCI
eIF3b Prt1—90 kDa p116 p84 p82 RRM
eIF3c Nip1—93 kDa p110 p104 p105 PCI
eIF3d – p66 Moe1a p66 –
eIF3e – p48 Int6a p51 PCI
eIF3f – p47 Csn6 p32 MPN
eIF3g Tif35—33 kDa p44 Tif35 p33 RBD
eIF3h p40 p40b p38 MPN
eIF3i Tif34—39 kDa p36 Sum1 p36 WD repeats
eIF3j Hcr1—35 kDa p35 – – –
eIF3k – p28 – p25 PCI
eIF3l – p67 – p60 PCI
eIF3m – GA17 Csn7Bb – PCI
The ‘conserved’ core subunits are highlighted in bold type, the ‘functional’ core subunits are underlined, and the ‘dispensable’ ones are in italics
 MPN Mpr1p and Pad1p N-terminal conserved domain; PCI 26S proteasome, COP9 signalosome and eukaryotic initiation factor eIF3 conserved 
domain; RBD RNA-binding domain; RRM RNA-recognition motif; S6K1 ribosomal protein S6 kinase 1; WD conserved regions of approxi-
mately 40 amino acids typically bracketed by Trp–Asp
a  Subunits contained in S. pombe Int6 eIF3 complex
b  Subunits contained in S. pombe Csn7B eIF3 complex
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in vitro methionyl-puromycin synthesis assay [21]. Accord-
ingly, the mammalian eIF3 complex consists of five subu-
nits (eIF3-a, -b, -c, -g, -i) that represent a ‘conserved’ core 
essential for translation initiation in vivo, and the remaining 
‘noncore’ subunits that appear to be evolutionarily divergent 
and serve to modulate its activity [5, 14, 20].
The function of each subunit of eIF3 has first been inves-
tigated in S. cerevisiae. Deletion or mutation of eIF3a [24, 
25], eIF3b [15, 26], eIF3c [27], eIF3g [28], or eIF3i [20, 28, 
29] in yeast leads to a vast reduction in protein synthesis, 
suggesting that each of these five subunits is required for 
eIF3 integrity. The role of each subunit and the minimum 
combination of components required for the formation of 
an active and functional core have also been investigated 
in mammalian eIF3 [30]. By using a baculovirus-based 
coexpression system, recombinant eIF3 complexes lack-
ing different individual subunits have been reconstituted. 
Remarkably, deletion studies showed that the rate of the 
protein synthesis does not change by knockdown of the 
two evolutionarily conserved subunits, eIF3g and eIF3i, in 
HeLa cells, and the eIF3 activity remains unaltered after 
deletion of the three non-conserved subunits eIF3-d, -k, -l 
[30]. Therefore, eIF3-g, -i, -d, -k, -l subunits are not essen-
tial for eIF3 activity but might be involved in translational 
control of specific mRNAs or in particular cellular condi-
tions [30]. Hence, the functional core of mammalian eIF3 
consists of three conserved subunits, eIF3-a, -b, -c, and 
three non-conserved subunits, eIF3-e, -f and -h. These three 
last subunits might serve to stabilize the eIF3-abc complex 
which directly participates in translation initiation [30]. In 
vitro stepwise reconstitution of human eIF3 subunits has 
revealed the architectural features of this factor. The dimer 
of subunits eIF3a and eIF3c serves as a central scaffold to 
which most of the other subunits bind. This dimer directly 
interacts with the subunits eIF3e, -k, -l and -m containing 
the PCI domain (the 26S proteasome, COP9 signalosome 
and eukaryotic initiation factor eIF3 conserved domain) and 
with the subunits eIF3-f and-h containing a MPN (Mpr1p 
and Pad1p N-terminal conserved domain) to form a highly 
stable PCI/MPN octamer. Subunits -d, -b, -g, -i, and -j then 
finalize the assembly of the eIF3 complex [11].
eIF3 function in cell cycle regulation, translational 
regulation, and cancer
The global protein synthesis in mammals occurs mainly in 
the G1 phase of a cell cycle and is reduced during mitosis. 
This process is modulated by several translation initiation fac-
tors [31]. The first studies that associated two eIF3 subunits, 
eIF3a and eIF3b, to cell cycle regulation were performed in 
S. cerevisiae. Both subunits are essential for the G1-S phase 
transition in yeast [32, 33]. A study on the eIF3a expression in 
mammalian cells has shown that its levels oscillate during the 
cell cycle and its maximum of expression is detected in the S 
phase, indicating that eIF3a may be a translational regulator 
for proteins important for S phase entrance [34]. Additionally, 
the subunits eIF3a [35], eIF3e [36, 37], eIF3k [38] and eIF3f 
[39] have been found in both cytoplasm and nucleus, indicat-
ing that these factors may shuttle between the two subcellular 
localizations according to cell cycle progression.
Proper execution of the cell cycle requires the synthesis 
and activation of key proteins at specific times. The most 
prevalent mechanism for regulating the overall rate of pro-
tein synthesis involves the phosphorylation of the initiation 
factors. Besides phosphorylation, the rate of protein synthe-
sis is regulated by other mechanisms and post-translational 
modifications of the translational machinery, such as meth-
ylation of lysine or arginine residues and O-glycosylation 
[40]. Recent reports confirm the role of the eIF3 factor in 
regulation of translation initiation rate [40–42]. However, 
the molecular mechanisms by which the function of eIF3 
is regulated are poorly understood. A mass spectrometric 
approach has been used to determine post-translational 
modifications that regulate the activity of eIF3 during the 
translation initiation process (Table 2). A total of 29 phos-
phorylation sites and several other post-translational modi-
fications (loss of N-terminal methionine and/or N-terminal 
protein acetylation) have recently been identified [10].
Alternatively, an indirect regulation of the activity of 
eIF3 is performed by association of its subunits with other 
proteins involved in the regulation of protein synthesis. For 
example, the subunit eIF3e binds p56 in interferon-treated 
or virus-infected mammalian cells, and inhibits the transla-
tion in vitro and in vivo [43, 44]. The subunit eIF3g inter-
acts with Paip1, a Poly (A)-binding protein and stimulates 
translation initiation [45], whereas the subunits eIF3h and 
eIF3f interact with TRC8, a ubiquitin E3 ligase, and inhibit 
protein synthesis, possibly through ubiquitilation of eIF3 or 
some other translational components [46]. These mecha-
nisms and interacting partners render eIF3 a pivotal player 
in controlling the protein synthesis and degradation.
A proper level of translation initiation is necessary to 
regulate cell proliferation, since the hyperactivation or the 
down-regulation of the rate of the protein synthesis con-
tributes importantly to cell malignancy. The contribution 
of eIF3 to oncogenesis and maintenance of the cancer state 
has been demonstrated in several studies [47–49]. Amongst 
the 13 subunits constituting eIF3, overexpression of subu-
nits eIF3-a, -b, -c, -h, -i, and -m has been detected in sev-
eral different solid tumors and in several different cancer 
cell lines (Table 3; for literature citations, see [42, 47, 48]. 
The correlation of abnormal eIF3 subunit levels and can-
cer indicates that eIF3 has an important role in determin-
ing the balance between cell proliferation and apoptosis. 
A study performed on NIH3T3 fibroblasts, stably transfected 
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with five individual eIF3 subunit cDNAs, has confirmed 
that their overexpression contributes to malignant pheno-
type [48]. Ectopic overexpression of eIF3-a, -b, -c, -h or -i 
induces an increase in protein synthesis rate, the resistance 
to apoptosis, and the oncogenic transformation of NIH3T3 
cells. Hence, eIF3 may play a causal role in neoplasia, and 
the misregulation of translation may be a contributory fac-
tor to cancer pathology [48]. It has been demonstrated that 
the overexpression of a single eIF3 subunit causes malig-
nant transformation and induces an increase in eIF3 activity, 
which in turn stimulates the translation of mRNAs involved 
in cell proliferation. Zhang et al. [48] have suggested that 
transforming subunit overexpression leads to the prefer-
ential stimulation of so-called “weak” mRNAs, which are 
translated more efficiently considering the abundant pres-
ence of secondary structures in their 5′-UTRs. Generally, 
“weak” mRNAs encode proteins involved in promoting 
cell growth and proliferation, such as c-myc, cyclin D1 and 
growth factors. Thus, the increase of “weak” mRNA prod-
ucts stimulates the malignant transformation of cells.
Two other eIF3 subunits, eIF3e and eIF3f, are downregu-
lated in human breast/lung carcinomas and melanoma/pan-
creatic cancer, respectively [50–54]. Low eIF3e expression 
is considered as a significant factor in predicting poor prog-
nosis for nonsmall cell lung cancer [52]. It may be likely 
that these factors have a causal role in cancer development 
inasmuch as their decrease removes the restraints that block 
the protein synthesis and stimulates the selective translation 
of oncogenic proteins involved in cell proliferation [53, 54].
The f subunit of eIF3
In 2003, Shi et al. [39] showed, for the first time, that in 
human cells the noncore f subunit of the mammalian eIF3 
multiprotein complex acts as a negative regulator of trans-
lation. Furthermore, in mammalian cells, eIF3f inhibits 
Table 3  Translational factor alterations in cancers
Subunit Observed modification Cancer association
eIF3a Increased expression Mouse melanoma, 
human breast, cervical, 
esophageal, lung, and 
gastric cancers
eIF3b Increased expression Human breast carcinoma
eIF3c Increased expression Human testicular  
seminomas
eIF3e Decreased expression Human breast and lung 
carcinomas
eIF3f Decreased expression Pancreas, vulva, ovary, 
breast, small intestine 
tumors, and melanoma
eIF3h Increased expression Human breast, prostate, 
hepatocellular carci-
nomas
eIF3i Increased expression Cadmium transformed 
NIH3T3 cell lines
eIF3m Increased expression Human colon cancer
Table 2  Identification of eIF3 protein subunits and their corresponding post-translational modifications using a mass spectrometric analysis [10]








eIF3a Q14152 166,758.3 86 Loss of Met-1, phosphorylation (Ser-881, Ser-1198, Ser-1336b, Ser-1364b)
eIF3b P55884 93,093.7 77 Acetylation (Met-1), phosphorylation (Ser-83, Ser-85, Ser-119, Ser-125b, 
Ser-152, Ser-154, Ser-164)
eIF3c Q99613 106,143.8 65 Phosphorylation (Ser-9, Ser-11, Ser-13, Ser-15, Ser-16, Ser-18, Ser-39, 
Ser-166c, Thr-524b, Ser-909c)
eIF3d O15371 63,972.9 74 Not found
eIF3e P60228 52,131.8 84 Loss of Met-1, acetylation (Ala-2)
eIF3f O00303 37,554.8 79 Loss of Met-1, acetylation (Ala-2), phosphorylation (Ser-258b)
eIF3g O75821 35,639.8 83 Loss of Met-1, phosphorylation (Thr-41, Ser-42)
eIF3h O15372 40,010.4 89 Phosphorylation (Ser-183b)
eIF3i Q13347 36,501.9 93 Not found
eIF3j O75822 29,293.2 81 Loss of Met-1, acetylation (Ala-2), phosphorylation (Ser-11, Ser-13,  
Ser-20, Thr-109c)
eIF3k Q9UBQ5 24,970.6 75 Loss of Met-1, acetylation (Ala-2)
eIF3l Q9Y262 66,637.9 70 Loss of Met-1, acetylation (Ser-2)
eIF3m Q7L2H7 42,413.8 74 Loss of Met-1, acetylation (Ser-2)
a  Calculated from the theoretical average mass of the corresponding eIF3 protein subunit plus any post-translational modifications identified
b  Found only after TiO2 phosphopeptide enrichment
c  Found only after Ga(III) IMAC or TiO2 phosphopeptide enrichment
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protein synthesis at the translational level and not by affect-
ing mRNA levels [55]. Translation initiation can be cap-
dependent or cap-independent/IRES-dependent. It is not 
clearly known whether eIF3f specifically inhibits one of 
these two types of translation. However, the silencing of 
eIF3f increased both cap-dependent and IRES-dependent 
translation, indicating a suppressive role of eIF3f on both 
translation initiation mechanisms [56]. Furthermore, it has 
been recently demonstrated that the f subunit plays a role 
in the inhibition of HIV-1 replication. Overexpression of 
N-terminal 91 amino acids of eIF3f or full-length eIF3f 
drastically restricts HIV-1 replication by interfering with 
the 3′-end processing of HIV-1 mRNAs and reducing their 
nuclear and cytoplasmic levels [57, 58].
Intracellular localization
Under normal conditions, most of the endogenous eIF3f 
is bound to 40S ribosomal subunit [55]. However, confo-
cal microscopy images of human melanoma cells show that 
eIF3f is localized at both cytoplasmic and nuclear levels 
[39]. Other eIF3 subunits, such as eIF3a, eIF3e and eIF3k, 
have been reported to have nuclear localization [35–38]. In 
fact, there are at least two different types of eIF3 complexes 
localized in both the cytoplasm and the nucleus of cells. 
Hence, eIF3 is considered as a ‘dynamic’ complex, where 
‘dynamic’ means that it may contain a different and variable 
number of subunits [59, 60]. The cytoplasmic eIF3 complex 
contains the subunits eIF3a-c and f, whereas the nuclear 
one lacks the subunits eIF3a and f [60]. What correlates this 
finding and the microscopy results?
It has been demonstrated that the phosphorylation of 
eIF3f may specifically increase its association with other 
eIF3 core complex subunits. In particular, during apoptosis, 
eIF3f is directly phosphorylated by the cyclin-dependent 
kinase CDK11p46 in living cells [60], and is incorporated 
into a micro-complex containing eIF3b and eIF3c, but not 
eIF3a. By cell fractionation, it has been observed that this 
complex precipitates with the nucleus in the insoluble frac-
tion of the cells. Nevertheless, eIF3f can also associate in 
a smaller complex consisting of eIF3a, eIF3b and eIF3c 
in the soluble fraction of both normal and apoptotic cells 
[60]. Therefore, under normal conditions, the nuclear eIF3 
contains eIF3b and eIF3c and, during apoptosis, the phos-
phorylated eIF3f joins the nuclear complex. The model 
currently suggested is that the translation initiation can be 
regulated during apoptosis by the phosphorylated eIF3f 
binding to different sub-fractions of the eIF3 complex [60]. 
This finding, coupled with the fact that eIF3f is a Mov34 
family member, led Shi et al. [39] to elaborate the hypoth-
esis that this factor may have a nuclear function in mRNA 
metabolism such as splicing or transport. It is also possible 
that the nuclear eIF3 complex has functions other than trans-
lation initiation. For example, the synthesis of ribosomes in 
eukaryotes takes place in the nucleus and then ribosomes 
are exported to the cytoplasm. Shi et al. [60] suggest that 
CDK11p46 may regulate the function of the nuclear eIF3 
complex by phosphorylating eIF3f, considering that cyclin-
dependent kinases are involved in ribosome biogenesis and 
nucleolar organization.
Regulation of eIF3f activity
The eIF3f subunit is a Mov34 family member, containing 
an MPN motif, which is found in two other macromolecu-
lar complexes homologous to eIF3, the COP9 signalosome 
and the 19S proteasome [5, 6, 61, 62]. The presence of a 
MPN domain in complexes with apparently divergent func-
tions, such as protein synthesis, signal transduction, and 
protein degradation, has been explained by the fact that this 
domain is probably necessary to promote complex assembly 
and is required for proper interactions between subunits of 
these complexes [63]. Recent crystallographic studies have 
revealed that there are two classes of MPN domains, one 
possessing a metalloprotease activity and a second possess-
ing a structural function [64, 65]. The subunits eIF3f and 
eIF3h contain the second type of MPN domain, which is 
responsible for protein–protein interactions and for protein 
stability [64, 65]. The crucial role of this domain in deter-
mining the cellular function and the intracellular behaviour 
of eIF3f has been confirmed by several studies. In 2006, Shi 
et al. [55] showed that this domain, and more precisely the 
amino acid region spanning residues 170–248, is respon-
sible for the translation inhibition function of eIF3f. Fur-
thermore, it has been demonstrated that an eIF3f activating 
phosphorylation site is located in the Mov34 domain [60]. 
The phosphorylation status of this subunit can significantly 
influence its association with eIF3 core complex, its intra-
cellular localization, and its function in the regulation of 
protein synthesis rate and in the control of the subtle balance 
between cell growth and cell death (see below). Moreover, 
several intracellular interacting partners of eIF3f have been 
identified (Fig. 1) using yeast two-hybrid screens. In most 
identified partners, the interactions are mediated by the Mov 
domain, suggesting that it may play a central role in regulat-
ing the activity of this subunit.
Apoptosis versus cell growth: the importance of eIF3f rate
Phosphorylation of eIF3f during apoptosis
Using a yeast two-hybrid system, Shi et al. [39] showed 
that endogenous cyclin-dependent kinase 11 (CDK11) and 
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eIF3f protein can interact and that their interaction can be 
strengthened by the stimulation of apoptosis.
The CDK11 kinases belong to a large family of p34cdc2-
related kinases [66] containing at least 20 CDK11 isoforms 
that are differentially expressed in mammalian tissues and 
regulate diverse cellular functions. The largest CDK11p110 
isoform is associated with cyclin L and various splicing fac-
tors, and is involved in the regulation of transcription and 
RNA splicing in proliferating cells [67, 68]. Expression 
of the CDK11p110 is ubiquitous and constant throughout 
the cell cycle [69]. During Fas- and tumor necrosis factor-
induced cell death, CDK11p110 is activated by proteolytic 
cleavage by caspase-3. Caspase-3 processing removes the 
N-terminal part of the protein, which contains nuclear trans-
location signals and is responsible for protein stability, and 
generates a smaller 46- to 50-kDa protein (CDK11p46) con-
taining the catalytic kinase domain [70, 71].
After anti-Fas or staurosporine treatments in human 
melanoma cells, the caspase-processed C-terminal fragment 
CDK11p46 strongly interacts with eIF3f via its Mov34 
domain [39] and, due to its kinase activity, phosphoryl-
ates eIF3f inducing the inhibition of translation (Fig. 2). 
The mutation of the phosphate transfer site in CDK11p46 
abrogates the phosphorylation of eIF3f protein. Two dif-
ferent phosphorylation sites have been identified in eIF3f 
during apoptosis: Ser46 [39] and Thr119 [60]. CDK11p46 
phosphorylates both sites. Thr119 is located in the Mov34 
domain of eIF3f, which is important for both the transla-
tional inhibitory function and the eIF3f interaction with 
CDK11p46. The biological consequence of the phospho-
rylation of eIF3f during apoptosis is not completely known. 
The phosphorylation status of eIF3f can significantly influ-
ence its association with the eIF3 core complex and its 
function in the regulation of translation and apoptosis [60]. 
Considering that the phosphorylations on Ser46 and Thr119 
have been detected in cells undergoing apoptosis, it has 
been postulated that eIF3f may be involved in the inhibition 
of the protein synthesis when phosphorylated, acting as a 
downstream death executer.
eIF3f expression levels in cancer and apoptotic cells
The biological role of eIF3f in translation and apoptosis in 
tumor cells has been investigated by Shi et al. [39, 53–56, 60]. 
Transcriptome analysis has shown that endogenous eIF3f 
expression level changes from one cell type to another and 
from normal to tumor cells [55]. Furthermore, the eIF3f 
protein level also increases during apoptosis with maximal 
expression at 36 h after stimulation [55].
Using a cancer profiling array and real-time reverse tran-
scription PCR, eIF3f transcript levels have been shown to be 
downregulated in most human tumors relative to matched 
normal tissues [55]. In particular, 100 % of pancreas and 
vulva tumors, 90 % of breast tumors, 71 % of melanomas, 
and 70 % of ovary and small intestine tumors showed a 
significant decrease of eIF3f expression [55]. Using loss of 
heterozygosity and gene copy number analyses, it has been 
demonstrated that there is an allelic loss of eIF3f gene in 
human melanoma and in pancreatic cancer cells [53, 54]. 
No mutations are responsible for the decreased eIF3f expres-
sion in these two cancer types [53, 54].
The molecular mechanism by which eIF3f protein 
expression decreases, contributing to cancer development, 
is unclear. One possible explanation is that the decrease of 
a negative regulator of translation like eIF3f may lead to 
an increased eIF3 activity, which in turn stimulates transla-
tion of specific mRNAs encoding for proteins involved in 
cell proliferation [53, 54]. eIF3f was also found to interact 
with mTOR and S6K1. The decrease of eIF3f expression 
may deregulate the function of the mTOR pathway, which 
in turn leads to increased translation of oncogenic pro-
teins and malignant transformation [53, 54]. Finally, eIF3f 
Fig. 1  Schematic representa-
tion of the intracellular interact-
ing partners of the eIF3f subunit
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is ubiquitously expressed in all tissues and is associated 
with both subpolysomal particles and polysomes. eIF3f is 
localized at both cytoplasmic and nuclear levels according 
to the cell cycle phase and is able to associate to different 
sub-fractions of the eIF3 complex. Probably, these various 
multiproteins complexes are implicated in the role of eIF3f 
in discriminating the mRNAs to be translated into normal 
cells, and may also reflect the deregulation of the transla-
tional pathway in tumor cells.
eIF3f overexpression in cancer inducing apoptosis
Enforced expression of eIF3f inhibits translation, cel-
lular growth and proliferation, and induces apoptosis in 
melanoma and pancreatic cancer cells [53–55]. Ectopic 
expression of eIF3e and eIF3f subunits in stably trans-
fected NIH3T3 fibroblasts also inhibits cell growth and 
proliferation [48]. Western blot analyses have demonstrated 
that eIF3f induces apoptosis in caspase 3/7 and in a Bcl-2-, 
Bax- or Bcl-XL-independent manner [55]. It is still unclear 
whether decreased eIF3f expression is the cause, rather than 
the consequence, of malignant transformation. Knockdown 
of endogenous eIF3f by siRNA attenuates apoptosis in mel-
anoma cells after treatment with staurosporine as apoptotic 
agent [55]. Wen et al. [56] have stably knocked down endog-
enous eIF3f in normal human pancreatic ductal epithelial 
cells (HDPE) and have observed increased cell prolifera-
tion, clonogenicity, apoptotic resistance, survival, resist-
ance to chemotherapy drug, mesenchymal morphology, 
and migration. eIF3f-silenced cells also show an increased 
cell size, nuclear pleiomorphism, aneuploidy, and cell cycle 
abnormality. By using an ex vivo 3D-cell culture system, 
they have also shown that eIF3f-silenced HPDE cells form 
more irregular masses with abnormal architecture and 
polarity (recapitulating malignant tumors in vivo), while 
control cells develop into a single-layer epithelial hollow 
spheres (resembling normal pancreatic ductal structure in 
vivo). eIF3f-silenced HPDE cells proliferate in an anchor-
age-independent manner. These observations confirm that 
eIF3f is an important negative regulator of cell growth and 
proliferation, and the decrease of its expression contributes 
to tumor cells’ evading apoptosis via upregulation of protein 
synthesis [56].
A link between translation initiation and rRNA degradation
Besides the hypotheses described above to explain how 
decreased eIF3f may contribute to cancer development, a 
Fig. 2  Schematic representation of eIF3f interactions during apopto-
sis. Upon apoptotic stimulation, CDK11p110 is cleaved by caspase 3 
to generate a CDKp46 that interacts strongly with the Mov34 domain 
of eIF3f and phosphorylates it at Ser46 and Thr119. According to 
Wen et al.’s [56] hypothesis (left side), phosphorylated eIF3f inter-
acts with hnRNP K and promotes rRNA degradation by interfering 
with rRNA protective function of hnRNP. According to Walter et al.’s 
[73] hypothesis, under normal conditions (right side), Mss4 is tightly 
bound to eIF3f, inhibiting its phosphorylation and subsequent asso-
ciation with eIF3 protein complex and pro-apoptotic functions. After 
prolonged stress-induced apoptosis, Mss4 is downregulated, lead-
ing to a release of eIF3f, which is phosphorylated by the CDK11p46 
kinase and the translation initiation results inhibited
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further model linking the translation initiation factor and 
rRNA degradation has been proposed by Wen et al. [56]. 
This model finds its basis in the observation that eIF3f-
transfected cancer cells show a significant decrease of 60S 
and 80S ribosomes and 60S/40S ribosomal subunit ratio, 
and an increase in RNA absorbance during apoptosis [55]. 
It is still unclear whether the reduced 60S ribosomal subu-
nit contributes to or is a result of apoptosis. The increasing 
of the absorbance is correlated to an increased amount of 
rRNA degradation, which contributes to the apoptotic pro-
cess [55]. The major rRNA degraded in eIF3f-transfected 
cells is the 28S rRNA followed by the 18S rRNA in a minor 
rate [55]. How exactly eIF3f induces rRNA degradation is 
unclear. However, as shown for other eIF3 subunits, the 
translation may be inhibited by specific eIF3f binding to 
RNAs and their consequent degradation [29]. The discovery 
that eIF3f can interact with the heterogenous nuclear ribo-
nucleoprotein K (hnRNP K) during apoptosis in melanoma 
and HPDE cells corroborates this model [56]. hnRNP K 
is a RNA-binding protein responsible for the maintenance 
of RNA stability by binding to the 3′-UTR of the mRNAs. 
Yeast three-hybrid screens and RNA pull-down assays 
have shown that hnRNP binds to 18S and 28S rRNA [72]. 
In human cells, dissociation of hnRNP from rRNA con-
tributes to rRNA degradation during apoptosis [56]. How-
ever, whether hnRNP K regulates rRNA degradation is not 
known. Considering that hnRNP K protects rRNA from 
degradation whereas eIF3f promotes this process, Wen et al. 
[56] have proposed that eIF3f may interact with hnRNP K 
during apoptosis and promote rRNA degradation by inter-
fering with its rRNA protective function (Fig. 2). In other 
words, eIF3f sequesters hnRNP K and inhibits its binding 
to rRNA, which leads to increased rRNA degradation and 
attenuated translation.
The rRNA synthesis and degradation in normal cells 
needs to be perfectly balanced in order to maintain homeo-
stasis of protein synthesis. Under physiological conditions, 
eIF3f competes with rRNA for hnRNP K binding. This con-
tributes to the maintenance of the homeostasis of rRNA level 
and translation in cells. Increased eIF3f expression contrib-
utes to apoptosis via hnRNP K sequestration and increased 
rRNA degradation. Loss of eIF3f contributes to tumorigen-
esis via the increased binding of hnRNP K to rRNA and 
an increased rRNA level. Currently, it is still unclear where 
and how normal human rRNA is degraded during various 
physiologic or pathologic cellular processes; however, eIF3f 
might play a role in mRNA and rRNA degradation.
Mss4: the neutralizing agent of eIF3f translation inhibitory 
effect
Starting from an investigation into the regulatory properties 
of the mammalian suppressor of Sec4 (Mss4) in response to 
cellular stress, Walter et al. [73] have recently demonstrated 
that this protein can act as an anti-apoptotic agent by direct 
binding to eIF3f. High expression levels of Mss4 protein are 
beneficial for cells, as they protect them from stress-induced 
apoptosis. The expression of Mss4 is strongly regulated by 
stress stimuli at both transcription and post-transcriptional 
levels: it is upregulated at early stages of stress stimulation, 
but it declines with prolonged stimulation. Yeast two-hybrid 
screens have indicated that the most abundant Mss4 inter-
action partner is eIF3f, and studies on A7 melanoma cells 
have shown that Mss4 neutralizes the translation inhibitory 
effect of eIF3f [73]. Thus, Mss4 is probably involved in 
the regulation of protein translation, and its association to 
eIF3f protects cells from apoptosis. In other words, eIF3f is 
a negative regulator of translation: its overexpression makes 
apoptosis easier, whereas its downregulation has the oppo-
site effect. Under normal conditions, Mss4 is tightly bound 
to eIF3f, inhibiting its phosphorylation and subsequent 
association with eIF3 complex. At early stages of stress 
stimulation, increasing amounts of Mss4 protein efficiently 
bind the eIF3f preventing its interaction with CDK11p46. 
When Mss4 proteins in cells drop-down owing to ongoing 
stress, the CDK11p46 can phosphorylate the released eIF3f. 
The translation initiation is inhibited and apoptosis is acti-
vated (Fig. 2).
Atrophy versus hypertrophy: the importance of eIF3f
Hypertrophy
In muscle cells, the regulation of protein synthesis rate also 
has an important role in the control of cell growth. Muscular 
hypertrophy and atrophy are two opposite and mechanisti-
cally linked phenomena regulating muscle cell size, finely 
determined throughout a balance between new protein 
accumulation and degradation of pre-existing proteins [74]. 
A major mediator of skeletal muscle hypertrophy is the 
serine/threonine-specific protein kinase Akt1. Two major 
downstream branches of the Akt pathway, which are rel-
evant to muscle hypertrophy, are the mTOR pathway, which 
is activated by Akt, and glycogen synthase kinase 3β, which 
is blocked by Akt. Both pathways control the protein syn-
thesis [74].
The kinase mammalian target of rapamycin (mTOR) 
has recently emerged as a key regulator of mammalian cell 
growth that integrates signals from growth factors, nutri-
ents, and energy status to control protein synthesis and 
other cell functions [75, 76]. As the name implies, mTOR is 
selectively inhibited by rapamycin, a drug used as an immu-
nosuppressant in organ transplantation. The role of mTOR 
in muscle growth has been demonstrated by in vivo stud-
ies showing that rapamycin blocks overload hypertrophy 
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and regenerating muscle growth [77, 78]. The effect of 
mTOR on the translation machinery and protein synthesis 
is executed by phosphorylation of the ribosomal protein S6 
kinases and of 4E-BP1, a repressor of the cap-binding pro-
tein eIF4E [79, 80]. mTOR and S6K1 maneuver on and off 
the eIF3 translation initiation complex in a signal-dependent 
fashion [79]. In fact, the eIF3 complex acts as a scaffolding 
platform that associates with mTOR and S6K1 in a growth-
factor and rapamycin-sensitive manner. Under normal 
conditions, S6K1 is bound to the eIF3 complex, whereas 
mTOR association is greatly reduced. Following an activat-
ing signal, such as insulin stimulation, mTOR is recruited 
to the eIF3-preinitiation complex, leading to phospho-
rylation of the bound and inactive S6K1. Phosphorylated 
S6K1 is released from the eIF3 complex, and interacts with 
PDK1, which promotes a second phosphorylation of S6K1. 
Activated S6K1 then phosphorylates eIF4B, which is then 
recruited to the eIF3-preinitiation complex and promotes the 
recruitment of other initiation factors and the translation of 
mRNAs encoding proteins involved in muscle hypertrophy 
(Fig. 3, upper panel) [79]. Thus, eIF3, mTOR, and S6K1 
coordinate the assembly of a translation initiation complex 
with enhanced translational capacity under conditions of 
nutrient and energy sufficiency. The understanding of how 
this assembly is controlled is still incomplete. However a 
physical and functional link exists between these proteins. 
Yeast two-hybrid screens have revealed that both mTOR 
[80] and S6K1 [79] physically interact with the f subunit 
of eIF3. Particularly, the inactive hypophosphorylated form 
of S6K1 physically associates with the Mov34 domain of 
eIF3f [81]. Thus, mTOR and S6K1 mediate assembly of the 
translation preinitiation complex through dynamic protein/
Fig. 3  Schematic representa-
tion of the intracellular signals 
characterizing the hypertrophic 
(upper panel) and atrophic 
(lower panel) pathways in 
muscle cells. During hyper-
trophy, mTOR phosphorylates 
S6K1, which is released from 
eIF3 complex, and phosphoryl-
ated again by PDK1. Activated 
S6K1 phosphorylates eIF4B, 
which promotes the recruit-
ment of other initiation factors 
and the translation of mRNAs 
encoding proteins involved in 
muscle growth. During atrophy, 
the ubiquitin ligase MAFbx 
is upregulated and S6K1 is 
accumulated in its inactive 
hypophosphorylated form. By 
binding the Mov34 domain, 
MAFbx transfers polyubiquitin 
chains on eIF3f and promotes 
its degradation by the protea-
some and block the synthesis of 
proteins involved in muscle cell 
growth
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protein interchange and might control the function of eIF3 
[80].
Translational regulation of eIF3f
The mRNA encoding for the eIF3f factor contains at the 
5′ end a relatively short stretch of 6–12 pyrimidines, called 
the terminal oligopyrimidine (TOP) sequence, and con-
sequently its mRNA is known as TOP mRNA [82]. The 
TOP sequence serves as a cis-acting element necessary 
for a growth-associated translation regulation [83]. The 
translational control of TOP mRNAs is used by cells to 
coordinate the synthesis of different ribosomal proteins, 
elongation factors, and several other proteins associated 
with the assembly or function of the translational apparatus 
[83]. Interestingly, among the initiation factors, only eIF3e, 
eIF3f and eIF3h exhibit the characteristics of TOP mRNAs 
[82]. A polysome mRNA analysis on HeLa, HEK293 and 
NIH3T3 cells has revealed that eIF3e, eIF3f and eIF3h 
mRNAs are mainly associated with subpolysomal particles 
in quiescent or growth-arrested cells, but mostly associ-
ated with polysomes in growing cells [82]. Consequently, 
the fact that these three eIF3 subunits are encoded by TOP 
mRNAs is considered relevant for their role in the growth-
associated translation regulation.
It is classically known that mTOR complex 1 (mTORC1) 
regulates cell growth and proliferation through modulation 
of protein synthesis in response to growth factors, hormones 
and amino acids [84]. In a recent study, it has been dem-
onstrated that the mTORC1 kinase specifically controls 
the translation of TOP mRNAs through the eIF4E-binding 
proteins (4E-BPs) and the eIF4G1 initiation factor [85]. In 
eIF4E-dependent initiation, mTORC1 phosphorylates the 
4E-BPs promoting their dissociation from the cap-binding 
protein eIF4E. Active eIF4E then associates to eIF4G1, 
which interacts with eIF3 resulting in the assembly of 
the 43S pre-initiation complex on the mRNA [75]. When 
mTORC1 is inactivated by rapamycin or Torin1, dephos-
phorylated 4E-BPs bind eIF4E and thereby prevent its asso-
ciation with eIF4G1 and the consequent activation of TOP 
mRNA translation [85].
In 2010, Csibi et al. [86] reported that the decreased activ-
ity of mTORC1 kinase is correlated with the degradation of 
eIF3f and the accumulation of unphosphorylated forms of 
S6K1 during muscle atrophy. In contrast, during terminal 
muscle differentiation, the amount of eIF3f increases as 
well as mTORC1, leading to an increase in S6K1 activa-
tion and phosphorylation of rpS6 and 4E-BP1 [86]. They 
also observed that rapamycin treatment destabilizes the 
mTORC1/eIF3f interaction in differentiated myotubes, and 
that ablation of eIF3f in muscle cells prevents mTORC1 
activity and phosphorylation of S6K1, rpS6 and 4E-BP1 
[86].
Thus, in muscle cells, the eIF3f translation may be regu-
lated in an mTORC1-dependent manner.
Atrophy
Atrophy is a decrease in cell size mainly caused by a loss 
of organelles, cytoplasm and proteins. A major contribution 
in understanding muscle atrophy comes from the pioneer-
ing studies on gene expression profiling performed indepen-
dently by Gomes and Bodine [87, 88]. The idea to compare 
gene expression in different models of muscle atrophy leads 
to the identification of a subset of genes that are commonly 
up- or down-regulated. Since all the diseases used for the 
experiments of microarray (i.e., diabetes, cancer cachexia, 
chronic renal failure, fasting, and denervation) have muscle 
atrophy in common, the up or down genes are believed to 
regulate the loss of muscle components and are called atro-
phy-related genes or atrogenes [89]. Together, these findings 
indicate that muscle atrophy is an active process controlled 
by specific signaling pathways and transcriptional programs 
[74]. Furthermore, the two most induced genes encode for 
two muscle-specific ubiquitin ligases, atrogin-1/MAFbx 
and MuRF1, which are upregulated in different models of 
muscle atrophy and are responsible for the increased pro-
tein degradation through the ubiquitin–proteasome system 
[87, 88]. These two genes are actually the best markers for 
muscle atrophy and could be considered as master genes for 
muscle wasting.
Ectopic expression of MAFbx in myotubes leads to 
atrophy and appears to be essential for accelerated mus-
cle protein loss [90]. Interestingly, during atrophy, MAFbx 
physically interacts with the f subunit of eIF3 via its Mov34 
domain [91], leading to its ubiquitination and its degradation 
by the proteasome (Fig. 3, lower panel) [90]. The silencing 
of MAFbx expression by small hairpin RNA interference 
prevents eIF3f degradation in myotubes undergoing atrophy 
[91]. In C2C12 myotubes that undergo atrophy, MAFbx 
accumulates in the nucleus and triggers the translocation of 
eIF3f from the cytoplasm to the nucleus. The translocation 
of the f subunit between the two compartments may repre-
sent a mechanism for regulating its activity during atrophy.
Interestingly, eIF3f can itself act as an enzyme by deu-
biquinating the transmembrane receptor Notch1 [92]. Notch 
1 is involved in a highly conserved signaling pathway 
essential for development and is monoubiquitinated during 
its activation. To enter the nucleus and fulfill its transcrip-
tional functions, this receptor needs to be deubiquitinated. 
The f subunit acts as a positive regulator of Notch signaling. 
The activated form of Notch is able to interact with eIF3f 
only in the presence of the E3 ubiquitin ligase Deltex [92]. 
It remains to be elucidated whether eIF3f works as a deu-
biquinating enzyme outside the translation complex or in 
association with the whole translation initiation complex.
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The role of eIF3f in atrophy and hypertrophy
By using an inducible protein expression system, it has been 
demonstrated that the genetic activation of eIF3f is suffi-
cient to block atrophy and induces a massive hypertrophy. 
This cellular growth is associated with an increase of sarco-
meric proteins but not the muscle regulatory factors such as 
MyoD and/or myogenin [91]. eIF3f is upregulated during 
terminal differentiation of skeletal muscle and absent in the 
undifferentiated embryonic rhabdomyosarcoma. Hence, in 
skeletal muscle, eIF3f can act as a ‘translational enhancer’ 
that increases the efficiency of the structural muscle protein 
synthesis leading to muscle hypertrophy in vitro and in vivo. 
These findings are consistent with previous suggestions that 
overload-induced hypertrophy is due to an increase in trans-
lational capacity and/or translational efficiency [93, 94]. 
Thus, eIF3f plays an important role in controlling muscle 
mass and size.
In constrast, the loss of eIF3f, due to MAFbx-mediated 
ubiquitination, induces atrophy in normal myotubes. Pro-
teins destined for degradation are marked by covalent link-
age with a chain of ubiquitin molecules on lysine residues 
for further degradation into short peptides by the 26 S pro-
teasome. Deletion studies, focused on the identification of 
the lysine residues marked by MAFbx, have shown that 
the target for proteasomal degradation is the C-terminal 
domain of eIF3f. This domain contains 6 C-terminal lysine 
residues that serve as ubiquitination sites. The mutation of 
these 6 lysine into arginine residues (mutant K5-10R) does 
not suppress the MAFbx-eIF3f interaction nor its activ-
ity. Thus, the C-terminal domain finely regulates eIF3f 
activity in skeletal muscle [90]. When levels of eIF3f are 
maintained by electroporation of the eIF3f K5-10R mutant 
into adult fibers, muscles are protected from atrophy [90]. 
The eIF3f mutant K5-10R induces a strong hypertrophic 
phenotype in cellulo and in vivo, and its overexpression 
provokes an enhanced ability in avoiding skeletal muscle 
atrophy [90].
The ubiquitination of eIF3f on C-terminal lysine resi-
dues may serve two functions: addressing eIF3f degradation 
specifically by MAFbx during skeletal muscle atrophy and 
regulating the translation of specific pools of mRNAs of key 
sarcomeric proteins [90].
Hence, atrophy and hypertrophy processes communicate 
with each other via the translation regulator eIF3f [81]. Its 
Mov34 domain is necessary for both S6K1 and MAFbx 
binding. In particular, muscles undergoing atrophy accu-
mulate the inactive hypophosphorylated form of S6K1, 
stimulating the MAFbx-mediated degradation of eIF3f 
(Fig. 3, lower panel). Whether MAFbx interacts with free 
eIF3f or with eIF3f molecules bound to S6K1 still remains 
unclear.
Conclusion
In the light of the eIF3f properties illustrated above, a global 
analysis of its interactome is necessary. Two opposite fea-
tures of eIF3f have emerged by analyzing the data available 
in the literature. This factor is able to act as both a ‘nega-
tive repressor’ of translation initiation [39] and a ‘trans-
lational enhancer’ [91], and as both a ‘downstream death 
executer’ in cancer cells [55] and a ‘cell growth enhancer’ 
in muscle cells [91]. The loss of eIF3f seems to contribute 
to tumorigenesis whereas its ectopic expression is sufficient 
to restore apoptosis in cancer cells. Interestingly, in normal 
myotubes, the genetic repression of eIF3f induces atrophy 
whereas genetic activation of eIF3f is sufficient to induce 
hypertrophy.
The same protein seems to act in two different ways 
according to the cell type considered. It is not clear whether 
the endogenous eIF3f protein rate is the cause or the effect of 
this behavior. However, a cell-type-specific role is believed 
to exist for eIF3f.
Several eIF3f interacting partners have been identi-
fied. During the apoptotic pathway, eIF3f is activated by 
CDK11p46, interacts with hnRNP K for RNA degradation, 
and is neutralized by Mss4. During the muscle cell growth, 
eIF3f interacts with mTOR/S6K1 to promote the assembly 
of the translation initiation complex and is degraded by 
MAFbx. A positive role in the activation of Notch signaling 
pathway has also been reported.
Moreover, two different types of eIF3 complexes (nuclear 
and cytoplasmic) have been found in the cell, suggesting that 
eIF3f could shuttle between the cytoplasm and the nucleus 
in a cell cycle-dependent manner.
All these data confirm that eIF3f has a multileveled con-
trol of multiple functions in the cells, outside its usual func-
tion in translation. Keeping that in mind, targeting eIF3f may 
be a strategy to reorganize different intracellular pathways 
and alter the basis of the balance between cell proliferation 
and apoptosis. Thus, eIF3f represents a lead candidate to 
use for biotherapeutic applications for both inhibiting the 
growth of cancer cells or muscle atrophy and, thus, prevent-
ing its progression into irreversible cachexia.
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